OverviewSuggest Edit

Imara is a company, dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. The Company offers IMR-687, an oral, and selective phosphodiesterase 9 (PDE9) inhibitor to treat patients with sickle cell disease by both reducing red blood cell sickling and blockage of blood vessels that are underlying causes of the pathology of sickle cell disease.

TypePublic
Founded2015
HQBoston, US
Websiteimaratx.com

Latest Updates

Employees (est.) (Feb 2020)20
Share Price (Mar 2020)$16 (-1%)

Key People/Management at Imara

Rahul D. Ballal

Rahul D. Ballal

CEO, Director
Willem H. Scheele

Willem H. Scheele

Chief Medical Officer
Michael P. Gray

Michael P. Gray

Chief Financial and Chief Operating Officer
Kevin B. Johnson

Kevin B. Johnson

Senior Vice President of Regulatory and Quality
Eleanor Lisbon

Eleanor Lisbon

Vice President of Clinical Development
Farah Natoli

Farah Natoli

Vice President of Program Management
Show more

Imara Office Locations

Imara has an office in Boston
Boston, US (HQ)
116 Huntington Ave 6th floor
Show all (1)

Imara Financials and Metrics

Imara Revenue

USD

Net income (FY, 2019)

(23.5m)

EBIT (FY, 2019)

(24.1m)

Market capitalization (26-Mar-2020)

265.2m

Closing stock price (26-Mar-2020)

16.0

Cash (31-Dec-2019)

4.9m
Imara's current market capitalization is $265.2 m.
USDFY, 2018FY, 2019

General and administrative expense

2.4m5.1m

R&D expense

8.2m19.0m

Operating expense total

10.7m24.1m

EBIT

(10.7m)(24.1m)
USDFY, 2018FY, 2019

Cash

7.4m4.9m

Prepaid Expenses

323.0k1.7m

Current Assets

7.7m30.6m

PP&E

442.0k
USDFY, 2018FY, 2019

Net Income

(11.3m)(23.5m)

Depreciation and Amortization

33.0k

Accounts Payable

477.0k750.0k

Cash From Operating Activities

(8.8m)(21.9m)
USDY, 2019

Financial Leverage

-0.7 x
Show all financial metrics

Imara Online and Social Media Presence

Embed Graph

Imara News and Updates

Imara sets IPO terms, expects to raise up to $80 million and be valued at up to $294 million

Imara Inc. set terms of its initial public offering, in which the biopharmaceutical company could raise up to $80.1 million, and be valued at up to $293.9 million. The Boston-based company is offering 4.45 million shares of common stock in the IPO, which is expected to price between $16 and $18 a s…

Arix Bioscience plc : Imara Files for Proposed Initial Public Offering in the United States

LONDON, Feb. 17, 2020 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that one of its portfolio companies, Imara Inc., ("Imara"), has filed a...

Pfizer-backed biopharma company Imara files for IPO

Pfizer Inc.-backed biopharma company Imara Inc. filed initial public offering documents late Friday with the Securities and Exchange Commission, planning to list on the Nasdaq Global Market under the ticker symbol "IMRA." According to the documents, Imara plans to raise $86.3 million, and Morgan Sta…

Arix Bioscience plc - Imara Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering in the United States

LONDON, Sept. 13, 2019 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company Imara, Inc. ("Imara"), has confidentially submitted a draft...

Imara Blogs

Imara Appoints Joelle Lufkin, M.P.H., as Senior Vice President of Development

Brings proven drug development and clinical operations leadership to the company’s continued clinical development of IMR-687 for sickle cell disease and beta-thalassemia Boston, Mass., February 6, 2020 – Imara Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializi…

Imara Submits Confidential Draft Registration Statement for Proposed Initial Public Offering

Boston, Mass., September 13, 2019 – Imara Inc. today announced that it has previously confidentially submitted a draft registration statement on Form S-1 to the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares t…

Imara Expands Management Team and Strengthens Expertise Across Strategic Functions as it Advances IMR-687 for Sickle Cell Disease and Beta Thalassemia

Company has appointed VPs of Program Management, Clinical Development, Technical Operations, Quality Assurance and Development Operations Cambridge, Mass., August 13, 2019 – Imara Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat…

Imara Presented Positive, Interim Phase 2a Data on IMR-687 for the Treatment of Sickle Cell Disease at the 24th Congress of the European Hematology Association

Company encouraged by interim 13-week data in trial designed to assess the safety and tolerability of IMR-687 and explore the potential efficacy of IMR-687 on clinical outcome measures relevant to sickle cell disease Cambridge, Mass., June 18, 2019 – Imara Inc., a clinical-stage biopharmaceutical co…

Imara to Present at the 24th Congress of the European Hematology Association

Cambridge, Mass., June 7, 2019 – Imara Inc., a clinical-stage biopharmaceutical company developing novel therapies for people living with sickle cell disease and other serious, inherited blood disorders, today announced that the company will deliver an oral presentation on IMR-687 at the 24th Congre…

Imara Announces FDA Fast Track Designation for IMR-687 for the Treatment of Sickle Cell Disease

Cambridge, Mass., May 29, 2019 – Imara, Inc., a clinical-stage biopharmaceutical company focused on sickle cell disease and other hemoglobinopathies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to IMR-687, the company’s lead product candidate f…

Imara Frequently Asked Questions

  • When was Imara founded?

    Imara was founded in 2015.

  • Who are Imara key executives?

    Imara's key executives are Rahul D. Ballal, Willem H. Scheele and Michael P. Gray.

  • How many employees does Imara have?

    Imara has 20 employees.

  • Who are Imara competitors?

    Competitors of Imara include ReViral, Sosei Heptares and Seres Therapeutics.

  • Where is Imara headquarters?

    Imara headquarters is located at 116 Huntington Ave 6th floor, Boston.

  • Where are Imara offices?

    Imara has an office in Boston.

  • How many offices does Imara have?

    Imara has 1 office.